Gainers

• Quince Therapeutics (NASDAQ:QNCX) stock rose 25.6% to $0.17 during Wednesday's pre-market session. The company's market cap stands at $7.7 million.
• LifeStance Health Gr (NASDAQ:LFST) shares moved upwards by 13.86% to $8.13. The market value of their outstanding shares is at $2.7 billion. As per the news, the Q4 earnings report came out today.
• Kairos Pharma (AMEX:KAPA) stock rose 11.74% to $0.64. The company's market cap stands at $11.9 million.
• Supernus Pharmaceuticals (NASDAQ:SUPN) stock rose 9.94% to $58.6. The company's market cap stands at $2.9 billion. The company's, Q4 earnings came out yesterday.
• Akari Therapeutics (NASDAQ:AKTX) stock moved upwards by 9.8% to $0.28. The market value of their outstanding shares is at $9.1 million.
• MediciNova (NASDAQ:MNOV) shares rose 9.62% to $1.48. The company's market cap stands at $66.3 million.

Losers

• Edesa Biotech (NASDAQ:EDSA) stock fell 10.6% to $1.35 during Wednesday's pre-market session. The company's market cap stands at $12.6 million.
• Fortrea Holdings (NASDAQ:FTRE) stock declined by 9.89% to $9.3. The company's market cap stands at $953.5 million.
• Lumexa Imaging Holdings (NASDAQ:LMRI) shares fell 9.66% to $13.0. The market value of their outstanding shares is at $1.3 billion.
• BioRestorative Therapies (NASDAQ:BRTX) shares fell 9.39% to $0.24. The company's market cap stands at $6.2 million.
• Inogen (NASDAQ:INGN) shares decreased by 9.25% to $5.3. The company's market cap stands at $158.5 million. As per the news, the Q4 earnings report came out yesterday.
• Lunai Bioworks (NASDAQ:LNAI) shares declined by 8.07% to $0.4. The market value of their outstanding shares is at $10.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.